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The objective of this study is to describe the relationships between dosing 
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•  Inclusion Criteria:  
   −  Age ≤ 17 years 
   −  Age ≥ 60 days  
   −  Treatment with IV vancomycin, with at least one trough 
concentration reported 
   −  Inpatient treatment from July 1, 2007 to June 30, 2011 at 
Lehigh Valley Health Network
•  Exclusion Criteria:  
   −  Inpatient treatment prior to July 1, 2007 or after June 30, 2011 
at Lehigh Valley Health Network
   −  Age > 17 years
   −  Age < 60 days  
   −  Patients with rapidly changing renal function at initiation of 
treatment
   −  Patients on hemodialysis prior to initiation of therapy 





•  Vancomycin is the antibiotic of choice for invasive infections 
caused by methicillin-resistant Staphylococcus aureus (MRSA).1 
•  The preferred method of vancomycin monitoring is the 
measurement of serum trough concentrations.2
•  The recommended trough concentration for adults is 10-20 mcg/ml 
and 15-20 mcg/ml for more serious infections.2,3   
•  In the pediatric population, the optimal vancomycin dose and target 
trough is unknown.   
   −  Children have increased clearance compared to adults and 
require higher doses per body weight to achieve a trough of 
10-20 mcg/ml.4 
   −  Vancomycin troughs less than 10 mcg/ml have been 
associated with treatment failure and the development of 
resistance.2
•  Vancomycin-induced nephrotoxicity, a rare but serious side effect, 
occurs in about 5-7% of patients.  This toxicity is more common in 
patients on high doses or concomitant nephrotoxic drugs.3,5   
•  There are limited published reports regarding optimal vancomycin 
dosing in pediatric patients.
A retrospective chart review of 
pediatric patients treated with 
intravenous vancomycin with 
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•  The goal of this retrospective review is to gather information 
regarding vancomycin dosing and resultant serum trough 
concentrations in pediatric patients. 
•  We will evaluate the effect of vancomycin dosing strategies on serum 
trough concentrations by separating patients into specific treatment 
groups based on total daily dose per body weight and evaluating the 
number of patients in each group achieving a target trough of 10-20 
mcg/ml. 
•  We will evaluate the effect of age on serum trough concentrations by 
separating pediatric patients into specific age groups and evaluating 
the number of patients achieving a target trough of 10-20 mcg/ml in 
each group and the average dose necessary to achieve that target.   
•  A secondary evaluation will identify patients with deteriorating renal 
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